Compare ALVO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALVO | GERN |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 911.0M |
| IPO Year | 2021 | 1996 |
| Metric | ALVO | GERN |
|---|---|---|
| Price | $4.07 | $1.47 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $8.00 | $2.17 |
| AVG Volume (30 Days) | 828.9K | ★ 10.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,065,000.00 |
| Revenue This Year | $13.28 | $26.91 |
| Revenue Next Year | $18.63 | $43.75 |
| P/E Ratio | $18.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.94 | $1.04 |
| 52 Week High | $9.25 | $2.01 |
| Indicator | ALVO | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 62.51 | 50.89 |
| Support Level | $3.10 | $1.44 |
| Resistance Level | $4.59 | $1.69 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 88.55 | 56.98 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.